Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase

American Journal of Hematology

Volumn 82, Issue 1, 2007, Pages 59-64

  Monaco, Sara ^a   Tsao, Lawrence ^a   Murty, V V ^a   Nandula, S V ^a   Donovan, Virginia ^b   Oesterheld, J ^a   Bhagat, Govind ^a   Alobeid, Bachir ^a,c  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c Howard Hughes Medical Institute   (United States)

Author keywords

ALK positive; Anaplastic large cell lymphoma; c myc; Leukemic phase; t(3; 8)(q26.2; q24) translocation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHILDHOOD CANCER; CHROMOSOME 3Q; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION 3; CHROMOSOME TRANSLOCATION 8; DISEASE COURSE; FATALITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE C MYC; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 8; FATAL OUTCOME; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA; LYMPHOMA, LARGE-CELL; MALE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC;

EID: 33845942927     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20758     Document Type: Article

References (28)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Pittaluga S, Wlodarska I, Pulford K, et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997;151:343-351.
3. Wlodarska I, De Wolf-Peeters C, Falini B, et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 1998;92:2688-2695.
4. Rosenwald A, Ott G, Pulford K, et al. t(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5) (p23;q35) in anaplastic large cell lymphoma. Blood 1999;94:362-364.
5. Liang X, Meech SJ, Odom LF, et al. Assessment of t(2;5) (p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol 2004;121:496-506.
6. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93: 3913-3921.
7. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 1999;93:2697-2706.
8. Onciu M. Behm FG, Raimondi SC, et al. ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis. Report of three cases and review of the literature. Am J Clin Pathol 2003;120:617-625.
9. Villamor N, Rozman M, Esteve J, et al. Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. Ann Hematol 1999;78:478-482.
10. Dalal BI, Chhanabhai M, Horsman DE, LeHuquet J, Coupland R. Anaplastic large-cell lymphoma presenting as acute leukemia. Am J Hematol 2005;79:164-165.
11. Raetz EA, Perkins SL, Carlson MA, Schooler KP, Carroll WL, Virshup DM. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expresssion in pediatric anaplastic large cell lymphomas. Am J Path 2002;161:875-883.
12. Merz H, Lange K, Gaiser T, et al. Characterization of a novel human anaplastic large cell lymphoma cell line tumorigenic in SCID mice. Leuk Lymphoma 2002;43:165-172.
13. Bayle C, Charpentier A, Duchayne E, et al. Leukaemic presentation of small cell variant anaplastic large cell lymphoma: Report of four cases. Br J Haematol 1999;104:680-688.
14. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Path 1993;17:859-868.
15. Inghirami G, Macri L, Cesarman E, Chadburn A, Zhong J, Knowles DM. Molecular characterization of CD30+ anaplastic large-cell lymphoma: High frequency of c-myc proto-oncogene activation. Blood 1994;83:3581-3590.
16. Lin P, Medeiros LJ, Yin CC, Abruzzo LV. Translocation (3;8)(q26;q24): A recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia. Cancer Genet Cytogenet 2006;166:82-85.
17. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 1997;11:2022-2031.
18. Rabin M, McClelland A, Kuhn L, Ruddle FH. Regional localization of the human transferrin receptor gene to 3q26.2-qter. Am J Hum Genet 1985;37:1112-1116.
19. Yoshida S, Kaneita Y, Aoki Y, Seto M, Mori S, Moriyama M. Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5′-RACE and LA-PCR analyses of biopsy samples. Oncogene 1999;18: 7994-7999.
20. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000; 96:2993-3000.
21. Felgar RE, Salhany KE, Macon WR, Pietra GG, Kinney MC. The expression of TIA-1 + cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): Correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum Pathol 1999;30:228-236.
22. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858.
23. Penny RJ, Blaustein JC, Longtine JA, Pinkus GS. Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases. Cancer 1991;68:362-373.
24. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996;88:4005-4011.
25. Meech SJ, McGavran L, Odom LF, et al. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood 2001;98:1209-1216.
26. Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol 2003;119:205-212.
27. Herling M, Rassidakis GZ, Jones D, Schmitt-Graeff A, Sarris AH, Medeiros LJ. Absence of Epstein-Barr virus in anaplastic large cell lymphoma: A study of 64 cases classified according to World Health Organization criteria. Hum Pathol. 2004;35:455-459.
28. Pitman SD, Rowsell EH, Cao JD, Huang Q, Wang J. Anaplastic large cell lymphoma associated with Epstein-Barr virus following cardiac transplant. Am J Surg Pathol 2004;28:410-415.